Marine Antitumor Peptide Dolastatin 10: Biological Activity, Structural Modification and Synthetic Chemistry
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Marine Antitumor Peptide Dolastatin 10: Biological Activity, Structural Modification and Synthetic Chemistry
Authors
Keywords
-
Journal
Marine Drugs
Volume 19, Issue 7, Pages 363
Publisher
MDPI AG
Online
2021-06-24
DOI
10.3390/md19070363
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Antineoplastic Agents. 607. Emetine Auristatins
- (2020) George R. Pettit et al. JOURNAL OF NATURAL PRODUCTS
- Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network
- (2020) Loredana Amoroso et al. EUROPEAN JOURNAL OF CANCER
- Quorum Sensing Inhibitors from Marine Microorganisms and Their Synthetic Derivatives
- (2019) Jianwei Chen et al. Marine Drugs
- Have marine natural product drug discovery efforts been productive and how can we improve their efficiency?
- (2019) Florbela Pereira Expert Opinion on Drug Discovery
- Marine-Derived Natural Compounds for the Treatment of Parkinson’s Disease
- (2019) Chunhui Huang et al. Marine Drugs
- Marine-Derived Natural Lead Compound Disulfide-Linked Dimer Psammaplin A: Biological Activity and Structural Modification
- (2019) Qinxue Jing et al. Marine Drugs
- Marine Compounds and Cancer: The First Two Decades of XXI Century
- (2019) Sergey A. Dyshlovoy et al. Marine Drugs
- Synthesis and evaluation of novel dolastatin 10 derivatives for versatile conjugations
- (2018) Shinya Yokosaka et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Marine natural products
- (2018) John W. Blunt et al. NATURAL PRODUCT REPORTS
- Recent Progress of Marine Polypeptides as Anticancer Agents Marine Polypeptides as Anticancer Agents
- (2018) Lanhong Zheng et al. Recent Patents on Anti-Cancer Drug Discovery
- Marine sponges of the genus Stelletta as promising drug sources: Chemical and biological aspects
- (2018) Qihao Wu et al. Acta Pharmaceutica Sinica B
- Antineoplastic Agents. 603. Quinstatins: Exceptional Cancer Cell Growth Inhibitors
- (2017) George R. Pettit et al. JOURNAL OF NATURAL PRODUCTS
- Antineoplastic Agents. 604. The Path of Quinstatin Derivatives to Antibody Drug Conjugates
- (2017) George R. Pettit et al. JOURNAL OF NATURAL PRODUCTS
- Antineoplastic Agents. 605. Isoquinstatins
- (2017) George R. Pettit et al. JOURNAL OF NATURAL PRODUCTS
- Synthesis and Evaluation of Dolastatin 10 Analogues Containing Heteroatoms on the Amino Acid Side Chains
- (2017) Julien Dugal-Tessier et al. JOURNAL OF NATURAL PRODUCTS
- Current Status and Future Prospects of Marine Natural Products (MNPs) as Antimicrobials
- (2017) Alka Choudhary et al. Marine Drugs
- Peptides, Peptidomimetics, and Polypeptides from Marine Sources: A Wealth of Natural Sources for Pharmaceutical Applications
- (2017) Rushikesh Sable et al. Marine Drugs
- A practical approach to asymmetric synthesis of dolastatin 10
- (2017) Wen Zhou et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- Synthesis and biological activity evaluation of dolastatin 10 analogues with N-terminal modifications
- (2017) Xin Wang et al. TETRAHEDRON
- TNF-α and IL-6 inhibitory effects of cyclic dipeptides isolated from marine bacteria Streptomyces sp
- (2016) Yedukondalu Nalli et al. MEDICINAL CHEMISTRY RESEARCH
- Screening for Marine Natural Products with Potential as Chemotherapeutics for Acute Myeloid Leukemia
- (2015) Espen Hansen et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Biologically active peptides: Processes for their generation, purification and identification and applications as natural additives in the food and pharmaceutical industries
- (2015) Ruann Janser Soares de Castro et al. FOOD RESEARCH INTERNATIONAL
- Discovery of Cytotoxic Dolastatin 10 Analogues with N-Terminal Modifications
- (2014) Andreas Maderna et al. JOURNAL OF MEDICINAL CHEMISTRY
- Clinical Status of Anti-Cancer Agents Derived from Marine Sources
- (2013) Ram Singh et al. Anti-Cancer Agents in Medicinal Chemistry
- Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors
- (2012) Christina M. Annunziata et al. INVESTIGATIONAL NEW DRUGS
- The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
- (2012) Peter D Senter et al. NATURE BIOTECHNOLOGY
- Anti-inflammatory cyclopeptides from the marine sponge Theonella swinhoei
- (2012) Carmen Festa et al. TETRAHEDRON
- Antineoplastic Agents. 592. Highly Effective Cancer Cell Growth Inhibitory Structural Modifications of Dolastatin 10
- (2011) George R. Pettit et al. JOURNAL OF NATURAL PRODUCTS
- Antitumor Peptides from Marine Organisms
- (2011) Lan-Hong Zheng et al. Marine Drugs
- A Straightforward Approach to Protected (S)-Dolaphenine (Doe), the Unusual Amino Acid Component of Dolastatin 10
- (2011) Uli Kazmaier et al. SYNTHESIS-STUTTGART
- EphA2 Targeted Chemotherapy Using an Antibody Drug Conjugate in Endometrial Carcinoma
- (2010) J. W. Lee et al. CLINICAL CANCER RESEARCH
- Antibody-Drug Conjugates for the Treatment of Non-Hodgkin's Lymphoma: Target and Linker-Drug Selection
- (2009) A. G. Polson et al. CANCER RESEARCH
- Tubulin-Interactive Natural Products as Anticancer Agents(1)
- (2009) David G. I. Kingston JOURNAL OF NATURAL PRODUCTS
- EphA2 Immunoconjugate as Molecularly Targeted Chemotherapy for Ovarian Carcinoma
- (2009) Jeong-Won Lee et al. JNCI-Journal of the National Cancer Institute
- Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance
- (2009) E. A. Perez MOLECULAR CANCER THERAPEUTICS
- Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer
- (2008) J. Horti et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, given weekly to advanced solid tumor patients for 3 weeks
- (2008) Nobuyuki Yamamoto et al. CANCER SCIENCE
- Microtubule Active Agents: Beyond the Taxane Frontier
- (2008) P. G. Morris et al. CLINICAL CANCER RESEARCH
- Microtubules: A dynamic target in cancer therapy
- (2008) Eddy Pasquier et al. IUBMB LIFE
- Natural products to drugs: natural product-derived compounds in clinical trials
- (2008) Mark S. Butler NATURAL PRODUCT REPORTS
- Drug development from marine natural products
- (2008) Tadeusz F. Molinski et al. NATURE REVIEWS DRUG DISCOVERY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now